Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
about
Decentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature reviewNext-generation antimicrobials: from chemical biology to first-in-class drugsMetalloid compounds as drugsAdvances in Development of New Treatment for LeishmaniasisIn vitro and in vivo activity of an organic tellurium compound on Leishmania (Leishmania) chagasiOpen-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseasesInfrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasisMiltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical StudyThe Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous LeishmaniasisMorinda citrifolia Linn. Reduces Parasite Load and Modulates Cytokines and Extracellular Matrix Proteins in C57BL/6 Mice Infected with Leishmania (Leishmania) amazonensisHyponatremia and risk factors for death in human visceral leishmaniasis: new insights from a cross-sectional study in Brazil.In vitro activity of the hydroethanolic extract and biflavonoids isolated from Selaginella sellowii on Leishmania (Leishmania) amazonensis.Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.A comparison of molecular markers to detect Lutzomyia longipalpis naturally infected with Leishmania (Leishmania) infantum.Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf?Identification and functional characterization of a novel bacterial type asparagine synthetase A: a tRNA synthetase paralog from Leishmania donovaniDevelopment and comparative evaluation of two antigen detection tests for Visceral Leishmaniasis.A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort StudyNovel Agents against Miltefosine-Unresponsive Leishmania donovani.Library of Seleno-Compounds as Novel Agents against Leishmania Species.Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosineDiscovery of 3,3'-diindolylmethanes as potent antileishmanial agents.A Replicative In Vitro Assay for Drug Discovery against Leishmania donovaniNew perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape.A comprehensive review of patented antileishmanial agents.Novel drug discovery for Chagas disease.Overview of dendritic cell-based vaccine development for leishmaniasis.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.Visceral Leishmaniasis in Southeastern Iran: A Narrative Review.Solute carrier protein family 11 member 1 (Slc11a1) activation efficiently inhibits Leishmania donovani survival in host macrophages.Imidazole-containing phthalazine derivatives inhibit Fe-SOD performance in Leishmania species and are active in vitro against visceral and mucosal leishmaniasis.Genetic Validation of Leishmania donovani Lysyl-tRNA Synthetase Shows that It Is Indispensable for Parasite Growth and Infectivity.Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of Visceral Leishmaniasis patients and the monitoring of their response to treatment.Screening a Natural Product-Based Library against Kinetoplastid Parasites.In Vitro antileishmania activity of sesquiterpene-rich essential oils from Nectandra species.Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation.Leishmaniasis in humans: drug or vaccine therapy?
P2860
Q26739026-E35F693E-A302-40E5-B73B-3F2AAA00F1FFQ26799749-BFF160F6-AA78-47AD-A241-1B91E758DF2CQ26822682-EF42B867-1068-4CED-9CCB-B5089942EC3AQ28082097-4E75F843-1D3C-4353-8968-78522A113567Q28484948-1048FC90-341A-4E59-80AE-F72E1B481527Q28535314-200C46BD-1D31-46D1-841B-AEF12C80E049Q28545229-7A9F32F0-0261-4B4E-BE50-F48C89B5BC38Q28551006-E1DEC1CD-4731-4494-9E4F-EF8EADCB1F5EQ28551926-2DF5E91C-C319-4E4C-9E4A-B874B54E167AQ28553787-916470E7-E892-4463-A201-8843B5A06BB4Q33439578-9F7B4AA2-D74F-42C3-9C63-C65829D3FF0FQ33587086-FCC043B9-1B98-4079-B700-43AC5DEF46C3Q33749424-9B17568A-0198-4719-B08B-DCFA4110106CQ33786761-F6613A28-0EDB-4BCE-9EDE-955B2A9861B1Q34139941-48647DB2-4AD1-44ED-94BF-FF0D3C83B599Q34705805-38463349-B39C-4A51-B93D-EABFC21FFE52Q35115121-252598D3-E140-4CA0-8EB3-83D7F52B8EC0Q36086604-32779032-7A5C-4028-BC39-E7B52A9B4223Q36141411-6B5B31A6-C21D-46FE-BAF3-2331AE6BA8ADQ36290836-F8B8CD37-8FBE-40B3-8825-E7953641AB4BQ36315604-7434E337-2B0F-4E45-BC0A-0B3FBBF75A87Q36380098-9677E234-C4D8-43E2-A000-0D723718623EQ36906590-6E460489-B261-4C9C-AFD6-69965E356F1BQ36933516-764178BD-6D72-4D07-9B23-8426C06CE409Q38296306-6370A4F3-D0E6-42EA-BE3B-D3F559004CFDQ38309761-33C0FA1B-C2C9-4962-AA45-70C7A3DB5282Q38770142-D71DF774-08A1-4BDE-A975-E0EAC60234FCQ38887861-A9A32322-03B2-4955-83CE-E246678E7480Q38939544-14412E6F-D6EB-4E9E-9264-33CD264D342EQ38966911-18EFF651-7F06-4603-8162-86311E469576Q39452262-54A35EB2-87C6-45AC-99A1-CEA3A2487D22Q40076960-84ECCC86-A920-43E7-939B-5DA4032D5D31Q41370122-AEF990D7-CDC8-499E-9971-99910F4344C1Q41570322-A2F8CD3D-9483-4CB5-9575-8C798C4F0B6BQ41656767-78B0A148-E785-4A4D-ACF4-D92D0AC84C83Q41993422-724030C8-E594-4306-9154-41A549CFD486Q42796077-C45CE26A-499A-4621-9264-29E7DB597073Q46252232-B732224E-35FE-4EB0-894F-02E7B99FD18EQ46581744-3401206C-870B-45E8-B1CD-0E2E49F49879Q47556262-E4C39FB6-7783-4F4D-A2FE-38E2AAB77AB9
P2860
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
@en
type
label
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
@en
prefLabel
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
@en
P2093
P2860
P1476
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
@en
P2093
Eric Chatelain
Helena Andrade Kim
Lucio H Freitas-Junior
P2860
P356
10.1016/J.IJPDDR.2012.01.003
P577
2012-01-28T00:00:00Z